Biopsy Devices Market

The biopsy device market is projected to reach USD 11.01  billion by 2030 from USD 7.27 Billion in 2024, at a CAGR 7.2 % from 2024 to 2030.

Biopsy devices are medical devices are used  to remove tissue samples from the body to diagnose diseases such as cancer. These devices include needles, forceps, procedure trays, tissue markers and visualization systems designed specifically for biopsy techniques such as fine-needle aspiration, core biopsy, or excisional biopsy. These devices ensure minimal invasion in sampling, with accuracy and by reducing discomfort to patients coupled with shorter recovery time. The new age biopsy devices  use imaging technology such as ultrasound, CT, or MRI guidance for greater accuracy.

To know about the assumptions considered for the study download the pdf brochure

Some of the prominent players operating in the market include Becton, Dickinson and Company (US), ), Devicor medical products, Inc (US), Medtronic (Ireland), Cardinal Health (US), B. Braun SE ( Germany),  Hologic, Inc (US), Olympus Corporation (Japan), Boston Scientific Corporation (US) and FUJIFILM Corporation (Japan) among others.

Devicor Medical Products, Inc. (US)

Devicor Medical Products, has the largest market share in the biopsy devices market largely because of its highly innovative and popular Mammotome® biopsy system. The system is a top VAB technology with high accuracy and low invasiveness, which has emerged as the go-to method for the diagnosis of breast cancer. Devicor has a very  well-established brand reputation, rigid global distribution channels, and strategic partnerships with healthcare professionals, guaranteeing its popularity among the stake holders and broad use of its products. The company is also involved in extensive investments in research and development, constantly improving the efficiency of biopsy devices.  Its wide-ranging portfolio, that comprises of  disposable biopsy needles and ultrasound-guided systems, addresses varied clinical requirements, reinforcing its strong leadership in the biopsy devices market.

Medtronic (Ireland)

Medtronic has a strong competitive advantage in the market for biopsy devices due to its minimally invasive biopsy solutions and strong research and development capabilities. For example, Medtronic produces sophisticated biopsy devices such as robotic biopsy devices developed to make the biopsy process more accurate and also increase patient comfort. The company's global reach, acquisitions, and partnerships with stakeholders also help cement its place in the industry. Being one of the leading players in the Biopsy Devices market, Medtronic has also established itself through an established network of distributors and continues to invest in the creation of new technologies, thus catering to the increasing requirement of early diagnostics and minimally invasive treatment of diseases.

Cardinal Helath (US)

Cardinal Health with its large product line, robust distribution network, and strategic purchases, makes it a leader in biopsy devices market. Cardinal Health provides a broad selection of high-quality biopsy devices  to address multiple clinical requirements in oncology and pathology. Its worldwide distribution chain and robust logistics infrastructure also provide it with the broad accessibility of biopsy instruments. This enhances its market dominance. Further, Cardinal Health has exploited strategic alliances and acquisitions to grow its product and technological strength base, enabling it to effectively rival market leaders in the industry.

Related Reports:

Biopsy Devices Market by Product (Core needle biopsy (Automatic, Disposable), Technology (Ultrasound,stereotactic), Application (Oncology, Gastroenterology, Bone & Bone marrow biopsy), End User (Diagnostic imaging centres) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]